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Abstract 
Background: In Brazil, 99.7 % of malaria cases occur in the Amazon region. Although the number of cases is decreas‑
ing, the country accounted for almost 60 % of cases in the Americas Region, in 2013. Novel approaches for malaria 
treatment open the possibility of eliminating the disease, but suboptimal dispensing and lack of adherence influence 
treatment outcomes. The aim of this paper is to show the results on dispensing practices, non‑adherence and deter‑
minants of non‑adherence to treatment of non‑complicated malaria.
Methods: The study was conducted in six high‑risk municipalities with Plasmodium vivax and Plasmodium falciparum 
transmission in the Brazilian Amazon and based on the theoretical framework of the Mafalda Project, which included 
investigation of dispensing and adherence. The World Health Organization Rapid Evaluation Method has been used 
to estimate sample size. Individuals over 15 years of age with malaria were approached at health facilities and invited 
to participate through informed consent. Data was collected in chart review forms focusing on diagnosis, Plasmodium 
type, prescribing, and dispensing (kind, quantity, labelling and procedures). Follow‑up household interviews comple‑
mented data collection at health facility. Non‑adherence was measured during the implementation phase, by self‑
reports and pill‑counts. Analysis was descriptive and statistical tests were carried out. Determinants of non‑adherence 
and quality of dispensing were assessed according to the literature.
Results: The study involved 165 patients. Dispensing was done according to the national guidelines. Labelling was 
adequate for P. vivax but inadequate for P. falciparum medicines. Non‑adherent patients were 12.1 % according to self‑
reports and 21.8 % according to pill‑counts. Results point to greater non‑adherence among all P. falciparum patients 
and among malaria non‑naîve patients. More patients informed understanding adverse effects than ‘how to use’ 
anti‑malarials.
Conclusions: Non‑adherent patients were mostly those with a P. falciparum diagnosis and those in their second 
or more malaria episode. New taxonomies and concepts on adherence stress the importance of focusing on the 
individual patient. Interventions targeted to and tailored for malaria patients must be addressed by health policy and 
implemented by managers and clinicians.
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Background
Despite the decrease in the number of malaria cases 
worldwide in the past decade, this disease remains a 
major public health problem. Brazil accounted for almost 
60 % of cases in the Americas Region, with 178,613 cases 
reported in the year 2013. Transmission still occurs in 
808 municipalities of the country [1, 2]; 99.7 % of cases 
occur in the Amazon region where Plasmodium vivax 
and Plasmodium falciparum co-exist, and to a lesser 
extent, Plasmodium malariae is present.
Following the recommendations of the Amsterdam 
conference in 1992, Brazil bases malaria control on early 
diagnosis and adequate treatment, while also favour-
ing prevention strategies [3]. For P. vivax malaria, for 
instance, the recommended treatment is the combina-
tion of chloroquine plus primaquine and this protocol 
remains unchanged.
In 2006, the Brazilian National Malaria Control Pro-
gramme (NMCP) introduced changes in P. falciparum 
malaria treatment, from quinine plus doxycycline plus 
primaquine to artemisinin combination therapy (ACT). 
According to NMCP, this treatment change resulted in 
a decrease in total number of P. falciparum cases, from 
24.9 % of all registered malaria cases in 2006, to <16.2 % 
in 2011 [1]. Novel approaches for malaria open the possi-
bility of eliminating the disease, in specific situations [4]. 
In this context the correct use of anti-malarials is tanta-
mount for disease control. This is one additional reason 
for studying treatment-based control policies.
Lack of treatment adherence is frequent in malaria [5], 
due to a number of factors that may be present, such as 
lack of prescription or written instructions, regimen 
complexity, adverse effects [6]. Sub-optimal dispensing is 
an important service determinant that may also be pre-
sent and influence treatment outcomes. These may lead 
to intermittent dosing and eventually to drug resistance 
[7].
Adherence has been measured by a series of direct 
and indirect methods, and is usually expressed as a per-
centage of total number of doses, according to dosing 
regimen [6, 8, 9]. Controlled studies have recently charac-
terized adherence as a multi-step or multi-phase process, 
involving initiation (or decision to start dosing), imple-
mentation (actual dosing history) and discontinuation 
(cessation) of the treatment regimen. The maintenance 
of treatment after initiation and before discontinuation is 
called persistence [7, 8]. In field conditions adherence, or 
non-adherence, may be investigated by questionnaires to 
produce estimated measures such as self-reports or pill 
counts. Both of these methods measure implementation 
and may clarify essential details regarding this phase, 
even if not other phases [10]. Overall, adherence remains 
an essential factor for malaria patients and although 
considerable work has been done to assess magnitude of 
adherence, several questions regarding adherence remain 
unanswered [11].
The main goal of this study is to show the results on 
dispensing practices, non-adherence to treatment dur-
ing the implementation phase and determinants of non-
adherence to treatment of non-complicated malaria in 
settings with P. vivax and P. falciparum transmission in 
high-risk municipalities of the Brazilian Amazon.
Methods
The methods employed in this work were based on the 
theoretical framework of the “Mafalda” Project (“Phar-
maceutical services for non-complicated malaria by P. 
vivax and P. falciparum in high-risk municipalities of 
the Brazilian Amazon: organization of services, prescrib-
ing, dispensing and adherence to treatment”). Initially, in 
order to subsidize the project, a comprehensive review of 
pharmaceutical services for malaria was carried out and 
published [12]. The framework comprising a logic model 
and 25 indicators was developed and subsequently pub-
lished [13]. The indicators included in the framework 
encompassed the following dimensions: context and 
organization of pharmaceutical services, prescribing, dis-
pensing and (implementation) adherence to treatment. 
The first two dimensions were developed and published 
[14]. This paper will focus on the implementation phase 
and examine non-adherence, by means of a careful 
examination of determinants, which include those linked 
to treatment regimen and those linked to health ser-
vices and care to malaria patients, including dispensing 
practices.
The method was based on World Health Organization 
(WHO) guidelines [15] and adapted by Management 
Sciences for Health (MSH) [16], in which evaluations of 
non-complicated malaria require a sample of not under 
600 patient registries (investigated at health facility level) 
is recommended [17], complemented by at least 150 
patients at household level.
Data collection instruments
Questionnaires, observation forms, interviews forms and 
chart review forms were used during field work, accord-
ing to the dimension that was being investigated [13]. 
Specific forms, for quantitative and qualitative data, were 
used for organization of services, prescribing and dis-
pensing. A chart review form compiled data on patient 
diagnoses, type of Plasmodium spp, treatment character-
istics (including prescribing), dispensing (dispensing pro-
cess, medicines received, in kind and quantity, labelling), 
information given to patient by health worker (regarding 
use of medicines, adverse effects and how to keep medi-
cine at home) and compliance to national guideline. For 
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the household survey, another data collection instru-
ment, for objective data, was applied, according to treat-
ment regime.
Field study
The investigation was carried out in six malaria high-risk 
municipalities of the Brazilian Amazon, selected accord-
ing to Annual Parasitic Index (API) and population. Up 
to four high-coverage primary health care facilities were 
selected to guarantee number of eligible individuals. 
Individuals of both genders, ≥15  years of age, exclud-
ing pregnant women, with parasitological confirmed 
mild malaria were followed throughout the study. More 
detailed information on the field study and participants 
may be found elsewhere [14].
All procedures for investigation of organization of 
services and prescribing were complemented by those 
designed to investigate dispensing and adherence. For 
information regarding these dimensions, patients were 
approached in a two-step process. Data collection during 
consultation at health facility and observation of dispens-
ing practices was complemented by household inter-
views. Patients that had been recruited for the first part 
of the investigation (consultation at health facility) were 
asked if household follow-up visit was welcomed, which 
indicated their inclusion in the next part of the investiga-
tion. Data was collected, according to P. falciparum or to 
P. vivax treatment, on the second or on the fifth day of 
treatment (D2 or D5), respectively.
Analysis
Analysis was based on the theoretical framework devel-
oped for the Mafalda Project [13]. Dispensing was char-
acterized by drugs dispensed according to prescription or 
indication, information given to patient during dispens-
ing; adequate labelling of medicines; patients reporting 
knowledge of treatment regimen and adverse effects. 
Adequacy of labelling was assessed by direct observa-
tion during dispensing of treatment regimens at health 
facilities.
Adherence was approached considering the assump-
tion that all patients initiated treatment on D0 and dis-
continued treatment at the end of D2 (P. falciparum) or 
D5 (P. vivax). Household visits occurred during the last 
day of treatment. Non-adherence was measured during 
the implementation phase, by self-reports (adherence 
accepted as no missed doses during treatment period) 
and pill counts (adherence accepted as quantity received 
as proxy of quantity consumed), both of which are 
expressed by percentages.
Determinants of non-adherence related to quality of 
dispensing were evaluated according to in-place require-
ments at facilities suggested by the literature [6, 7, 9, 18, 
19]. Other determinants related to disease (diagnosis, 
first malaria episode, general well-being in the present 
malaria episode) patient characteristics and treatment 
characteristics (first-line treatment, adverse effects, use 
of other medicines, care-seeking behaviour) were ana-
lysed according to adherence group. Among non-adher-
ent individuals, reasons given for non-adherence during 
household visit were described.
Statistical analysis
A simple test of differences between proportions was car-
ried out to investigate possible discrepancies in results, 
admitting a 95  % CI [20]. Concordance between meas-
ures of adherence (patient reports and pill counts) was 
carried out by calculation of the kappa index [21].
Ethical considerations
All participants were asked to sign an informed consent 
form and furthermore to give written agreement for 
household visits. The Sergio Arouca National School of 
Public Health, Oswaldo Cruz Foundation (Fiocruz) Eth-
ics in Research Committee gave study approval (Approval 
number 91/06; CAAE 0086.0.031.000.06).
Results
Dispensing
Treatment regimen was examined for 165 adult patients. 
This number was 10.0  % over the minimum number of 
patients required for the study of adherence as described 
in the study design. Of the 165 patients, 134 (81.2 %) had 
been diagnosed with P. vivax, all receiving first-line treat-
ment (Table  1) and 31 with P. falciparum, of which 16 
(51.6 % of P. falciparum patients) had received first-line 
treatment at the time of the study (Table 1). Twenty-eight 
patients (16.9  % overall) were experiencing their first 
malaria infection.
Observation of dispensing for these patients in health 
facilities first resulted in findings related to dispensing 
requirements. Dispensing of first-line regimens followed 
indication, and was done in accordance to the national 
guideline, for P. vivax as well as for P. falciparum. Among 
165 patients, 134 patients (81.2  %) received verbal 
instruction at dispensing; 112 (67.9 %) patients informed 
understanding of how to use the anti-malarials and 137 
(83 %) of their possible adverse effects.
In regard to labelling of medicines at dispensing, short-
comings related to name of medicine, dose or dosage 
form were observed. Labelling of chloroquine and pri-
maquine were adequate in 80 % of P. vivax regimens. At 
the time of data collection, first-line regimen for P. fal-
ciparum included quinine sulfate, doxycycline and pri-
maquine. However, labels for these medicines (quinine, 
n  =  16, doxycycline, n  =  16 and primaquine, n  =  16) 
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were all inadequate. Labels presented problems among 
the 15 patients receiving alternative P. falciparum treat-
ment, of which 14 received artemether–lumefantrine 
and primaquine. Inadequately labelled medicine was also 
dispensed to one patient receiving mefloquine and pri-
maquine for P. falciparum (Table 1).
Adherence and non‑adherence
One hundred and sixty-five patients were visited for 
household interviews during investigation of adherence 
(134 P. vivax patients on Day 5 and 31 P. falciparum 
patients on Day 2). Non-adherence during implemen-
tation measured by self-reports revealed 144 adherent 
patients (there was one missing measure for among P. 
vivax patients). Twenty patients (12.2  %), non-adherent 
in self-reports, informed they had stopped using at least 
one anti-malarial during treatment (Table 2).
Pill counts were conducted for 165 patients, and the 
quantity that they had in their possession, in relation to 
day of treatment, was accurate in 129 (78.2 %) and inac-
curate for 36 (21.8 %), patients designated as non-adher-
ent (Table  2). Concordance (kappa) between these two 
methods of measuring adherence was 0.74.
Table 2 also shows non-adherence determinants among 
individuals. P. falciparum patients were more prone to 
being non-adherent. This finding was significant for 
both measures of adherence implementation. Also sig-
nificant for implementation non-adherence according 
to pill count were results for non-naive malaria patients 
(p = 0.012). All other variables were non-significant.
Regarding P. falciparum patients, of the 12 non-adherent 
by pill-counts, 11 were on the first-line regimen and one 
was on artemether–lumefantrine and primaquine; of the 
eight non-adherent patients by self-reports, seven were on 
first-line treatment and one was on the alternative regimen 
with artemether–lumefantrine and primaquine. The dis-
tribution of non-adherence determinants by malaria type 
was not possible because of sample size.
Various possible reasons for non-adherence were given 
by individuals: forgetfulness (8 interviewees), occurrence 
of adverse effects (10), unwillingness to take medicine 
(6), alcohol consumption (1), ‘felt cured’ (3), other (20). 
Patients sometimes informed one, two or more reasons 
for non-adherence.
Discussion
The Mafalda Project (“Pharmaceutical services for non-
complicated malaria by P. vivax and P. falciparum in 
high-risk municipalities of the Brazilian Amazon: organi-
zation of services, prescribing, dispensing and adherence 
to treatment”) was developed in order to provide data of 
the situation of pharmaceutical services for malaria in 
municipalities at high risk for the disease in the Amazon 
[13, 14, 22, 23].
Previous results from the Mafalda Project have shown 
that in Brazil diagnostic procedures work well, but good 
prescribing practices are not performed in most munici-
palities. Other findings showed problems with organiza-
tion of pharmaceutical services—especially concerning 
stock management and drug storage [14]. There are no 
written instructions for the malaria patient and only oral 
Table 1 Diagnoses and  therapeutic regimens dispensed 
per malaria patient
Mafalda project, 2007
Type of malaria Therapeutic regimen n (%)
P. vivax Chloroquine and primaquine 134 (81.2)
P. falciparum Quinine sulfate, doxycycline and 
primaquine
16 (9.7)
Artemether–lumefantrine and  
primaquine
14 (8.5)
Mefloquine and primaquine 1 (0.6)
Total 165 (100)
Table 2 Non-adherence to anti-malarial treatment by self-
reports and pill counts
Mafalda project, 2007
* Fischer’s exact test
Characteristic Non‑adherence to anti‑malarial treatment
Pill counts Self‑reports
n (%) p value n (%) p value
Diagnosis
 P. vivax 24 (17.9) 0.012 12 (9.1) 0.014
 P. falciparum 12 (38.7) 8 (25.0)
First malaria episode
 Yes 2 (7.1) 0.044* 2 (7.1) 0.532*
 No 34 (24.8) 18 (13.3)
General well being in the present malaria episode
 Felt well/same as  
always
14 (20.6) 0.843 8 (11.8) 0.971
 Felt bad 21 (21.9) 11 (11.6)
First‑line treatment
 Yes 35 (23.3 %) 0.195* 19 (12.8 %) 0.697*
 No 1 (6.7 %) 1 (6.7 %)
Adverse effects
 Yes 21 (22.1) 0.917 11 (11.7) 0.823
 No 15 (21.4) 9 (13.0)
Uses other medicines
 Yes 12 (22.6) 0.860 6 (11.3) 0.813
 No 24 (21.4) 14 (12.6)
Seeked professional care during treatment
 Yes 4 (25.0) 0.749* 4 (25.0) 0.096*
 No 31 (20.9) 15 (10.2)
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guidance is received from technicians in endemic areas. 
Few qualified professionals (physicians) actually pre-
scribe [23]. Health workers have little formal education 
while training is informal or insufficient [23]. In this con-
text it seems difficult that these workers can effectively 
contribute to the processes that lead to adherence [6].
This study focused specifically on dispensing and 
adherence. Main findings in this study showed that 
dispensing was carried out according to the national 
guidelines. A greater proportion of patients informed 
understanding adverse effects over ‘how to use’ anti-
malarials. Labelling was adequate for P. vivax but inade-
quate for P. falciparum medicines. Self-reports accounted 
for 144 adherent patients and pill counts for 129.
Well-reported studies in the Brazilian Amazon have 
shown differences in adherence. One measured adher-
ence of P. vivax patients by a standardized scale and 
presented similar results as to range of non-adher-
ence, but an overall higher proportion of non-adherent 
patients—33.3  % [9]. Other studies showed lower per-
centages of non-adherent individuals: 9.6  % for non-
adherent P. vivax patients in Pará State [24] and 16  % 
non-adherence for P. vivax and P. falciparum patients in 
Mato Grosso [25].
This difference between methods and problems with 
questionnaire consistency has been described previously 
in the literature [6] and may account for the discrepancy. 
In this case, concordance between methods was 0.74. 
There was more implementation non-adherence among 
P. falciparum patients and among non-naive patients. 
Various previous malaria episodes in the same patient 
may be a barrier to complete treatment. Patients usually 
discontinue medication as they feel better and malaria-
savvy patients may disregard need to finalize treatment 
regimen [26]. Adequate dispensing with assertive infor-
mation as to the risks of not completing the treatment 
might have had a positive influence on these patients.
It is noteworthy to mention that lack of adequate label-
ling for P. falciparum medicines coincided with greater 
non-adherence for this group of patients. In regions 
where many patients are illiterate, family members who 
can read may provide support for better understanding 
of treatment regimens by patients, at least by reading 
the labels and instructions on how to use their medi-
cines. During the Mafalda Project, ACT had been intro-
duced by PNCM in certain areas of the Amazon but were 
labelled in English. This evidently worsened the situation. 
Recently this is undergoing change. Anti-malarials are 
now supplied in blisters labelled with symbols for better 
understanding [27]. Lack of written instructions for med-
icines, however, persists.
A greater number of patients (83  %) mentioned 
understanding adverse effects. These possible malaria 
treatment outcomes may be acutely felt by patients [23], 
and are therefore valued as a worthwhile reason for non-
adherence to treatment, as reported by ten individuals 
(27.8 %). Drugs with hazardous effects, even on the first 
dose, such as some anti-malarials, may cause ‘off–on’ epi-
sodes in treatment implementation, which account for 
abrupt changes to drug exposure, compromising treat-
ment response and fostering resistance [28, 29].
Results point to greater non-adherence among all P. fal-
ciparum patients and among malaria non-naive patients. 
For the first group, reasons may be associated to change 
in treatment regimens, from a three-medicine 5-day 
treatment to a single-medicine (ACT) 3-day treatment. 
Many patients experienced various episodes of P. falcipa-
rum malaria and were already accustomed to the treat-
ment regimen. With the lack of adequate instructions and 
labels, switches might be confusing. Another possibility 
is the acuteness of adverse effects with the traditional P. 
falciparum regimen (quinine sulfate, doxycycline, pri-
maquine), leading patients to discontinue treatment as 
soon as they feel a little better.
More than suboptimal dosing history (implementation 
of treatment regimen), early discontinuation (or short 
persistence) is the largest single factor for a decrease in 
adherence [7]. Three patients mentioned ‘feeling cured’ 
as a reason for early discontinuation. Individuals who 
experience malaria for the first time are apt to feel fear 
and recur to treatment, while those who have had more 
than one episode may feel more confident and not so 
treatment-dependent. Fourteen non-adherent patients 
were forgetful and-or unwilling to take their medicines. 
However, a precise understanding of discontinuation was 
not possible, due to methodological limitations. Visits 
were conducted at the end of treatment but actual treat-
ment discontinuation was not observed or measured.
Adherence is a crucial step for any pharmacological 
treatment. Acute-phase, complex treatments, such as 
anti-malarial treatment, oblige prescriber-patient col-
laboration mainly as to the initiation and implementation 
steps of adherence [8]. Interventions, such as the NMCP, 
may not be sufficient to secure adherence. Population-
targeted approaches would need to be developed for non-
adherent individuals, while tailored approaches would 
need to focus on the principal causes and determinants 
for non-adherence [28]. As such, these steps must begin 
to be addressed by health managers and clinicians. Rel-
evant information on non-adherence by malaria patients 
is essential for health-based interventions that aim to 
decrease therapeutic failure and emergence resistance for 
P. falciparum and P. vivax.
Plasmodium falciparum and non-naïve patients con-
stitute possible target groups for adherence interventions 
in malaria treatment [28]. Brazil has a low number of P. 
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falciparum cases [1] and the goal is to eliminate P. falci-
parum malaria before emergence of resistance to ACT 
[4]. However, this may prove to be difficult given the con-
text in the Amazon. As such, alternative and concurrent 
strategies [29] must be taken to improve treatment effec-
tiveness and retard resistance emergence. One of these 
strategies is improving adherence in all its stages (initia-
tion, implementation and discontinuation) [8] and iden-
tifying non-adherent patients. Tailoring interventions 
for individual non-adherent patients, on the other hand, 
is only possible through understanding the determinants 
associated with non-adherence [18, 28].
Studies on adherence cover many types of definitions 
of adherence and measures [8, 9]. Several employ self-
reports or pill counts, or both, in order to improve valid-
ity. This study presented both methods and concordance 
between them of 0.74, considered good [21]. Nonethe-
less, both methods may overestimate adherence—or 
underestimate non-adherence.
Concepts on adherence have traditionally followed a 
stepwise process. The WHO [19] has proposed five groups 
of adherence determinants—linked to health system, to 
disease, to the individual, to social-economic aspects, 
and to treatment-related aspects. Other authors [18, 30] 
have also studied adherence-related determinants. Apart 
from variables associated with the various determinants 
of adherence, Kardas and colleagues [18] point out that 
actual organizational processes—correct prescribing and 
adequate dispensing—have a direct impact on adherence 
and can invalidate control efforts (and in case of P. falci-
parum, elimination). This may be the case with malaria, 
mainly because of complex treatment regimens [6, 30].
Through controlled studies, new concepts associated 
with adherence have emerged which subvert previous 
understanding of how adherence should be measured 
[6, 8–10, 28]. This has consequences on how to design 
studies on adherence and on how limited may findings 
such as ours be on actually measuring adherence in a 
given population. This study is limited to implementation 
adherence and in that to overall percentages of imple-
mentation, not being able to acknowledge the actual 
links between prescribing and drug dosing histories, so 
well put by Blaschke and colleagues [7]. Nevertheless, by 
acknowledging information gathered on overall imple-
mentation non-adherence and its determinants, results 
may shed light on needs for policy interventions, such 
as close patient monitoring and preventive measures to 
curb lack of treatment effectiveness.
As the sample in this study was designed for a tra-
ditional measure of adherence, numbers produced an 
overall idea of adherent and non-adherent patients, in 
respect to treatment implementation. Determinants for 
non-adherence were consistent with the literature [10]. 
However, non-adherence caused by sub-optimal ini-
tiation or discontinuation could not be identified by this 
approach. The small sample also impeded us from distin-
guishing between non-adherent P. falciparum patients in 
respect to differences in treatment regimens.
Conclusions
This study produced an overview of non-adherence 
measured in the implementation phase and of deter-
minants associated with non-adherence among P. fal-
ciparum and P. vivax patients in the Brazilian Amazon. 
Non-adherent patients were mostly those with a P. fal-
ciparum diagnosis and those in their second or more 
malaria episode. In face of new taxonomies and concepts 
on adherence and because the emergence of resistance to 
ACT and other anti-malarials are of utmost importance 
to public health, interventions targeted to and tailored 
for malaria patients must be addressed by health policy 
and implemented by managers and clinicians.
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